Biosimilar Bevacizumab for Metastatic Colorectal Cancer Launched in India

by Reshma Anand on  June 28, 2016 at 12:46 PM Corporate News
RSS Email Print This Page Comment bookmark
Font : A-A+

One of the generic Indian pharmaceutical companies, Hetero Drugs has launched a biosimilar for the treatment of metastatic colorectal cancer (mCRC) in India.
Biosimilar Bevacizumab for Metastatic Colorectal Cancer Launched in India
Biosimilar Bevacizumab for Metastatic Colorectal Cancer Launched in India

The drug called as "Bevacizumab" has been approved by the Drug Controller General of India as the first-line of treatment for this type of cancer and will be marketed under the brand name 'cizumab'.

The product will be available in a single dose vial with two strengths, 100 and 400mg. Hetero will manufacture the drugs in the facility based in Hyderabad.

Dr BPS Reddy, CMD, Hetero Group of Companies said: "It has been an exciting journey for us in Biologics. Hetero's Bevacizumab is the third product in our biologics portfolio, after Darbepoetin alfa and Rituximab. We believe CizumabTM will be a cost-effective treatment option to patients in India."


Source: Medindia

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

Related Links

More News on:

Cancer and Homeopathy Colo-rectal cancer - Management Colorectal Cancer Cancer Facts Cancer Tattoos A Body Art Colon Polyps Colorectal Cancer Screening Colorectal Cancer Screening with Colonoscopy Colorectal Cancer Screening with Double-Contrast Barium Enema 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Stay Connected

  • Available on the Android Market
  • Available on the App Store

News Category

News Archive

Loading...